...
txg-img

10X Genomics Inc, Common Stock

TXG

GSN

$28.4

+$0.81

(2.94%)

1D
Industry: Life Sciences Tools & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.00B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
NM
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.46M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
1.60M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.89
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$26.3 L
$63.57 H
$28.4

About 10X Genomics Inc, Common Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Returns

Time FrameTXGSectorS&P500
1-Week Return2.19%0.68%1.78%
1-Month Return-23.32%-4.12%-2.68%
3-Month Return-37.22%0.49%3.81%
6-Month Return-20.53%14.32%23.25%
1-Year Return-45.79%6.35%24.23%
3-Year Return-85.61%20.92%26.71%
5-Year Return-46.14%72.3%88.05%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue245.89M298.85M490.49M516.41M618.73M[{"date":"2019-12-31","value":39.74,"profit":true},{"date":"2020-12-31","value":48.3,"profit":true},{"date":"2021-12-31","value":79.27,"profit":true},{"date":"2022-12-31","value":83.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue61.03M58.47M74.09M120.39M209.41M[{"date":"2019-12-31","value":29.14,"profit":true},{"date":"2020-12-31","value":27.92,"profit":true},{"date":"2021-12-31","value":35.38,"profit":true},{"date":"2022-12-31","value":57.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit184.86M240.38M416.40M396.02M409.31M[{"date":"2019-12-31","value":44.39,"profit":true},{"date":"2020-12-31","value":57.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.11,"profit":true},{"date":"2023-12-31","value":98.3,"profit":true}]
Gross Margin75.18%80.44%84.89%76.69%66.15%[{"date":"2019-12-31","value":88.56,"profit":true},{"date":"2020-12-31","value":94.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.33,"profit":true},{"date":"2023-12-31","value":77.93,"profit":true}]
Operating Expenses213.93M325.70M469.31M563.97M611.18M[{"date":"2019-12-31","value":35,"profit":true},{"date":"2020-12-31","value":53.29,"profit":true},{"date":"2021-12-31","value":76.79,"profit":true},{"date":"2022-12-31","value":92.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(29.07M)(85.32M)(52.91M)(167.94M)(201.87M)[{"date":"2019-12-31","value":-2907100000,"profit":false},{"date":"2020-12-31","value":-8532400000,"profit":false},{"date":"2021-12-31","value":-5291300000,"profit":false},{"date":"2022-12-31","value":-16794400000,"profit":false},{"date":"2023-12-31","value":-20186800000,"profit":false}]
Total Non-Operating Income/Expense(2.24M)(449.30M)(1.46M)12.14M(30.02M)[{"date":"2019-12-31","value":-18.41,"profit":false},{"date":"2020-12-31","value":-3699.79,"profit":false},{"date":"2021-12-31","value":-12.04,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-247.22,"profit":false}]
Pre-Tax Income(31.03M)(534.48M)(53.72M)(161.97M)(248.76M)[{"date":"2019-12-31","value":-3103300000,"profit":false},{"date":"2020-12-31","value":-53447600000,"profit":false},{"date":"2021-12-31","value":-5371500000,"profit":false},{"date":"2022-12-31","value":-16197100000,"profit":false},{"date":"2023-12-31","value":-24876300000,"profit":false}]
Income Taxes218.00K8.26M4.51M4.03M6.34M[{"date":"2019-12-31","value":2.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":54.61,"profit":true},{"date":"2022-12-31","value":48.81,"profit":true},{"date":"2023-12-31","value":76.75,"profit":true}]
Income After Taxes(31.25M)(542.73M)(58.22M)(166.00M)(255.10M)[{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}]
Income From Continuous Operations(31.25M)(542.73M)(58.22M)(166.00M)(255.10M)[{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(31.25M)(542.73M)(58.22M)(166.00M)(255.10M)[{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}]
EPS (Diluted)(0.56)(5.13)(0.52)(1.47)(2.17)[{"date":"2019-12-31","value":-56,"profit":false},{"date":"2020-12-31","value":-513,"profit":false},{"date":"2021-12-31","value":-52,"profit":false},{"date":"2022-12-31","value":-147,"profit":false},{"date":"2023-12-31","value":-217,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TXG
Cash Ratio 3.06
Current Ratio 4.69
Quick Ratio 4.11

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TXG
ROA (LTM) -12.22%
ROE (LTM) -32.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TXG
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.30

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TXG
Trailing PE NM
Forward PE 196.08
P/S (TTM) 6.65
P/B 5.56
Price/FCF 147
EV/R 6.18
EV/Ebitda NM
PEG 0.23

News

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:…

21 Mar, 2024 a 8:05 pm PR Newswire

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel | TXG Stock News

10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers'' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.

21 Mar, 2024 a 8:05 pm Stock Titan

10x Genomics unveils first products with advanced GEM-X technology

In a significant advancement for the field of single cell and spatial biology, 10x Genomics, Inc. (Nasdaq: TXG) announced the launch of its first two products leveraging the groundbreaking GEM-X technology architecture. The products, named Chromium Single Cell Gene Expression 3′ v4 and Chromium Single Cell Immune Profiling 5′ v3, mark a pivotal moment in […]

14 Mar, 2024 a 3:50 am Business News Today

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime . Curing these diseases would be invaluable. The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest , the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That means by the end of the decade their value would grow from $820 billion to $4.5 trillion! That could be why she is investing in the stocks of the biotechs utilizing CRISPR gene editing, RNA therapeutics and targeted protein degradation. Below are three top Cathie Wood biotech stocks to consider for your own portfolio. 10X Genomics (TXG) Source: Michael Vi / Shutterstock 10X Genomics (NASDAQ: TXG ) isn’t pursuing life-changing drug development itself but instead provides the tools researchers need to achieve their goals.

1 Mar, 2024 a 7:00 pm InvestorPlace

10X Genomics Inc at Stephens Investment Conference Transcript

10X Genomics Inc at Stephens Investment Conference Transcript

1 Mar, 2024 a 6:52 am GuruFocus

Q3 2023 10X Genomics Inc Earnings Call Transcript

Q3 2023 10X Genomics Inc Earnings Call Transcript

1 Mar, 2024 a 6:52 am GuruFocus

FAQs

What is 10X Genomics Inc share price today?

10X Genomics Inc (TXG) share price today is $28.4

Can Indians buy 10X Genomics Inc shares?

Yes, Indians can buy shares of 10X Genomics Inc (TXG) on Vested. To buy 10X Genomics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TXG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of 10X Genomics Inc be purchased?

Yes, you can purchase fractional shares of 10X Genomics Inc (TXG) via the Vested app. You can start investing in 10X Genomics Inc (TXG) with a minimum investment of $1.

How to invest in 10X Genomics Inc shares from India?

You can invest in shares of 10X Genomics Inc (TXG) via Vested in three simple steps:

  • Click on Sign Up or Invest in TXG stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in 10X Genomics Inc shares
What is 10X Genomics Inc 52-week high and low stock price?

The 52-week high price of 10X Genomics Inc (TXG) is $63.57. The 52-week low price of 10X Genomics Inc (TXG) is $26.3.

What is 10X Genomics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of 10X Genomics Inc (TXG) is NM

What is 10X Genomics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of 10X Genomics Inc (TXG) is 5.56

What is 10X Genomics Inc dividend yield?

The dividend yield of 10X Genomics Inc (TXG) is 0.00%

What is the Market Cap of 10X Genomics Inc?

The market capitalization of 10X Genomics Inc (TXG) is $3.00B

What is 10X Genomics Inc’s stock symbol?

The stock symbol (or ticker) of 10X Genomics Inc is TXG

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top